¼¼°èÀÇ ¼¼Æ÷ ¿ëÇØ ¹× ºÐȹ ½ÃÀå º¸°í¼­(2025³â)
Cell Lysis And Fractionation Global Market Report 2025
»óǰÄÚµå : 1682037
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,219,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,990,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,761,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼Æ÷ ¿ëÇØ ¹× ºÐȹ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 7.0%·Î 48¾ï 9,000¸¸ ´Þ·¯·Î ¼ºÀåÇÕ´Ï´Ù. ¿¹Ãø ±â°£ ÁßÀÇ ¼ºÀåÀº ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ÀÚ±Ý Áö¿ø Áõ°¡, È¿°úÀûÀÎ ¹æ¹ý¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä, À¯ÀüüÇÐ ¹× ´Ü¹éÁúüÇÐ ºÐ¾ßÀÇ ±â¼ú ¹ßÀü, ¸¸¼ºÁúȯ ¹× °¨¿°¼º ÁúȯÀÇ À¯º´·ü Áõ°¡ µî¿¡ ±âÀÎÇÕ´Ï´Ù. ¿¹Ãø ±â°£ Áß ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀÇ Áö¼ÓÀûÀÎ ¼ºÀå, ¿ëÇØ ¹× ºÐȹ °øÁ¤ÀÇ ÀÚµ¿È­ ¹× ·Îº¿È­ ¹ßÀü, ÀÓ»ó Áø´Ü ¹× ÀǾàǰ °³¹ß ºÐ¾ß¿¡¼­ÀÇ Àû¿ë È®´ë, ¼¼Æ÷ ºÐ¼®¿ë ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ¹× ·¦¿ÂĨ ±â¼úÀÇ ¹ßÀü, POC(Point-Of-Care) ¹× ºÐ»êÇü °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ Á߿伺 Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

¸ÂÃãÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÇâÈÄ ¼¼Æ÷ ¿ëÇØ ¹× ºÐȹ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸ÂÃãÀÇ·á´Â °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏÀ» Áúº´ Áø´Ü ¹× Ä¡·á¿¡ Ȱ¿ëÇÏ´Â »õ·Î¿î ÀÇ·á ÇàÀ§ÀÔ´Ï´Ù. ÀÌ ÀÇ·á¿¡¼­´Â ÀÇ·áÀû °áÁ¤°ú Ä¡·á¸¦ ȯÀÚ °³°³ÀÎÀÇ Æ¯¼º¿¡ ¸Â°Ô Á¶Á¤ÇØ¾ß Çϸç, ƯÈ÷ À¯ÀüÀÚ ±¸¼º¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ¼¼Æ÷ ¿ëÇØ ¹× ºÐȹÀº ´Ü¹éÁú, ¼¼Æ÷ ¼Ò±â°ü, ÇÙ»ê µî ȯÀÚÀÇ »ùÇÿ¡¼­ ƯÁ¤ ¼¼Æ÷³» ¿ä¼Ò¸¦ ºÐ¸®ÇÏ°í ºÐ¼®ÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á Á¤¹ÐÀÇ·á¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ °úÇÐÀÚ¿Í ÀÇ·á Àü¹®°¡µéÀº Áúº´ÀÇ ±Ùº»ÀûÀÎ ºÐÀÚ °úÁ¤À» Á¶»çÇÏ°í °¢ ȯÀÚÀÇ °íÀ¯ÇÑ ºÐÀÚÀû Ư¼º¿¡ µû¶ó ¸ÂÃãÇü Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î °³ÀθÂÃãÀÇ·áÀÇ ÀÌÇØ¿Í º¸±ÞÀ» ÃßÁøÇÏ´Â ¹Ì±¹ ´ÜüÀÎ °³ÀθÂÃãÀǷῬÇÕ(PMC)¿¡ µû¸£¸é 2022³â 10¿ù¿¡´Â ¿©·¯ À¯ÇüÀÇ ¾Ï, À¯Àü¼º Èñ±ÍÁúȯ, ´Ù¾çÇÑ ¸¸¼ºÁúȯ ¹× °¨¿°¼º Áúȯ ȯÀÚ¸¦ ´ë»óÀ¸·Î 75,000°³ ÀÌ»óÀÇ À¯ÀüÀÚ °Ë»ç Á¦Ç°°ú 300°³ ÀÌ»óÀÇ °³ÀθÂÃãÇü ÀǾàǰÀÌ ½ÃÀå¿¡ Ãâ½ÃµÉ °ÍÀ̶ó°í ÇÕ´Ï´Ù. µÉ °ÍÀÔ´Ï´Ù. µû¶ó¼­ ¸ÂÃãÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¼¼Æ÷ ¿ëÇØ ¹× ºÐȹ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼¼Æ÷ ¿ëÇØ ¹× ºÐȹ ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷Àº ½ÃÀå °æÀï·ÂÀ» °­È­Çϱâ À§ÇØ CGT(¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á) ¹ÙÀÌ·¯½º º¤ÅÍ ¿ëÇØ ŰƮ¿Í °°Àº ÷´Ü ¼Ö·ç¼Ç µµÀÔ¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ëÇØ ŰƮ´Â °£¼ÒÈ­µÈ AAV(¾Æµ¥³ëºÎ¼öü ¹ÙÀÌ·¯½º) ¿ëÇØ ¹æ¹ýÀ» Á¦°øÇϰí, ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ÌÀÇ ¿öÅ©Ç÷ο츦 Ç¥ÁØÈ­Çϸ鼭 SOP(Ç¥ÁØ ¿î¿µ ÀýÂ÷), ǰÁú°ü¸®, ¾ÈÀü¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 7¿ù µ¶ÀÏ¿¡ º»»ç¸¦ µÐ »ùÇà ¹× ºÐ¼® ±â¼ú ÇÁ·Î¹ÙÀÌ´õÀÎ QIAGENÀº »õ·Î¿î CGT ¹ÙÀÌ·¯½º º¤ÅÍ ¿ëÇØ ŰƮ¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ Å°Æ®´Â ¼¼Æ÷ ¿ëÇØ¾×À¸·Î ½ÃÀÛÇÏ´Â Á¤È®ÇÏ°í ±ÕÀÏÇÑ ÀýÂ÷·Î ¿©·¯ Ç÷ûÇüÀÇ ¹ÙÀÌ·¯½º ¿ª°¡¸¦ Á¤·®È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î CGT ¹ÙÀÌ·¯½º º¤ÅÍ ¿ëÇØ ŰƮ´Â ¹ÙÀÌ¿À Á¦¾à »ê¾÷À» À§ÇØ ºü¸£°Ô È®ÀåµÇ°í ÀÖ´Â QIAGENÀÇ µðÁöÅÐ PCR Æ÷Æ®Æú¸®¿À¸¦ º¸¿ÏÇÏ´Â °ÍÀ¸·Î, ÀÌ¹Ì ¼÷ÁÖ¼¼Æ÷ DNAÀÇ ÀÌ¿ùÀ» È®ÀÎÇÏ´Â 3À¯ÇüÀÇ QIAcuity Residual DNA Quantification Kit 3Á¾°ú ¾Æµ¥³ëºÎ¼öü ¹ÙÀÌ·¯½º(AAV) ¿ª°¡ ÃøÁ¤¿¡ »ç¿ëµÇ´Â 10Á¾ÀÇ QIAcuity Cell and Gene Therapy(CGT) dPCR Assays°¡ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ½ÃÀåÀÇ Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ´ë±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÇÕº´°ú Àμö

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Cell lysis is the process of breaking open a cell, which allows the release of its contents, while cell fractionation is a multi-step laboratory procedure used to divide a cell's organelles into various layers or fractions or sections.

The main types of cell lysis and fractionation are mammalian cells and microbial cells. Mammalian cells are eukaryotic cells that are derived from mammals and are used in cell culture and biomanufacturing of therapeutic proteins and viral vaccines. These are used for various applications, such as nucleic acid purification and isolation and protein purification and isolation, and are used by several end users, including research laboratories and institutes, biopharmaceutical, and biotechnology companies.

The main types of cell lysis and fractionation are mammalian cells and microbial cells. Mammalian cells are eukaryotic cells that are derived from mammals and are used in cell culture and biomanufacturing of therapeutic proteins and viral vaccines. These are used for various applications, such as nucleic acid purification and isolation and protein purification and isolation, and are used by several end users, including research laboratories and institutes, biopharmaceutical, and biotechnology companies.

The cell lysis and fractionation market size has grown strongly in recent years. It will grow from $3.42 billion in 2024 to $3.72 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing investments in life science research, growing focus on personalized medicine, high prevalence of diseases, technological advancements in cell lysis and fractionation methods, rising demand for biopharmaceuticals and biotechnology products.

The cell lysis and fractionation market size is expected to see strong growth in the next few years. It will grow to $4.89 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing focus on personalized medicine, increasing government funding for research, high demand for effective cell lysis and fractionation methods, technological advancements in the field of genomics and proteomics, rising prevalence of chronic and infectious diseases. Major trends in the forecast period include continued growth in the adoption of personalized medicine approaches, increasing integration of automation and robotics in lysis and fractionation processes, expansion of applications in clinical diagnostics and drug development, advancements in microfluidics and lab-on-a-chip technologies for cell analysis, growing emphasis on point-of-care and decentralized testing solutions.

A growing focus on personalized medicine is expected to propel the growth of the cell lysis and fractionation markets going forward. Personalized medicine is an emerging practice of medicine that uses an individual's genetic profile for the diagnosis and treatment of disease. It involves tailoring medical decisions and treatments to the individual characteristics of each patient, particularly focusing on their genetic makeup. Cell lysis and fractionation play a crucial part in precision medicine by making it possible to separate and analyze particular subcellular elements from patient samples, including proteins, organelles, and nucleic acids. This makes it possible for scientists and medical professionals to investigate the molecular processes that underlie illness and create customized treatments depending on the unique molecular traits of each patient. For instance, in October 2022, according to the Personalized Medicine Coalition (PMC), a US-based organization that promotes understanding and adoption of personalized medicine, more than 75,000 genetic testing products and 300 personalized medicines will be on the market for people with multiple types of cancer, genetic rare diseases, and a range of chronic and infectious diseases. Therefore, the growing focus on personalized medicine is driving the growth of the cell lysis and fractionation markets.

Major companies operating in the cell lysis and fractionation market are focused on introducing advanced solutions, such as CGT (cell and gene therapy) viral vector lysis kits, to gain a competitive edge in the market. These lysis kits offer a simplified AAV (Adeno-associated virus) lysis methodology that will improve SOPs (Standard Operating Procedures), quality control, and safety while standardizing bioprocessing workflows. For instance, in July 2023, QIAGEN, a Germany-based provider of sample and assay technologies, launched the new CGT Viral Vector Lysis Kit, which makes it possible to quantify virus titers for several serotypes with an exact and uniform procedure starting with cell lysates. The new CGT viral vector lysis kit complements QIAGEN's rapidly expanding digital PCR portfolio for the biopharma industry, which already includes three QIAcuity Residual DNA Quantification Kits to check for host cell DNA carryover and ten QIAcuity Cell and Gene Therapy (CGT) dPCR Assays for use in adeno-associated virus (AAV) titer quantification.

In December 2022, MilliporeSigma, a US-based pharmaceutical company, acquired Erbi Biosystems Inc. for an undisclosed amount. With this acquisition, MilliporeSigma aims to strengthen its portfolio and expertise in the field of bioreactors and cell culture technologies. Erbi Biosystems is the developer of the 2 ml micro-bioreactor platform technology known as Breez, which is a micro-scale, fully automated, functionally closed system. Erbi Biosystems Inc. is a US-based biotechnology company that offers microfluidic solutions to enable efficient and controlled cell lysis and fractionation.

Major companies operating in the cell lysis and fractionation market are Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Lonza Group AG, Illumina Inc., Beckman Coulter Inc., PerkinElmer Inc., IDEX Corporation, Bio-Rad Laboratories Inc., QIAGEN NV, Eppendorf AG, Miltenyi Biotec B.V. & Co. KG, Promega Corporation, Takara Bio Inc., Abcam plc, Cell Signaling Technology Inc., BioVision Inc., Diagenode LLC, Claremont BioSolutions LLC, Norgen Biotek Corp., Qsonica LLC, Labfreez Instruments Group Co. Ltd.

North America was the largest region in the cell lysis and fractionation market in 2024. The regions covered in the cell lysis and fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell lysis and fractionation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cell lysis and fractionation market consists of revenues earned by entities by providing cellular contents extraction, cytoplasmic separation, and cell disruption. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell lysis and fractionation market also includes sales of cell lysis instruments, cell lysis reagents, and consumables. Values in this market are 'factory gate' values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell Lysis And Fractionation Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell lysis and fractionation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cell lysis and fractionation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell lysis and fractionation market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Cell Lysis And Fractionation Market Characteristics

3. Cell Lysis And Fractionation Market Trends And Strategies

4. Cell Lysis And Fractionation Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cell Lysis And Fractionation Growth Analysis And Strategic Analysis Framework

6. Cell Lysis And Fractionation Market Segmentation

7. Cell Lysis And Fractionation Market Regional And Country Analysis

8. Asia-Pacific Cell Lysis And Fractionation Market

9. China Cell Lysis And Fractionation Market

10. India Cell Lysis And Fractionation Market

11. Japan Cell Lysis And Fractionation Market

12. Australia Cell Lysis And Fractionation Market

13. Indonesia Cell Lysis And Fractionation Market

14. South Korea Cell Lysis And Fractionation Market

15. Western Europe Cell Lysis And Fractionation Market

16. UK Cell Lysis And Fractionation Market

17. Germany Cell Lysis And Fractionation Market

18. France Cell Lysis And Fractionation Market

19. Italy Cell Lysis And Fractionation Market

20. Spain Cell Lysis And Fractionation Market

21. Eastern Europe Cell Lysis And Fractionation Market

22. Russia Cell Lysis And Fractionation Market

23. North America Cell Lysis And Fractionation Market

24. USA Cell Lysis And Fractionation Market

25. Canada Cell Lysis And Fractionation Market

26. South America Cell Lysis And Fractionation Market

27. Brazil Cell Lysis And Fractionation Market

28. Middle East Cell Lysis And Fractionation Market

29. Africa Cell Lysis And Fractionation Market

30. Cell Lysis And Fractionation Market Competitive Landscape And Company Profiles

31. Cell Lysis And Fractionation Market Other Major And Innovative Companies

32. Global Cell Lysis And Fractionation Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell Lysis And Fractionation Market

34. Recent Developments In The Cell Lysis And Fractionation Market

35. Cell Lysis And Fractionation Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â